Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.

Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS.

J Clin Invest. 2019 Jul 16;130. pii: 127613. doi: 10.1172/JCI127613.


Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.

Mohammad OS, Nyquist MD, Schweizer MT, Balk SP, Corey E, Plymate S, Nelson PS, Mostaghel EA.

Cancers (Basel). 2017 Dec 6;9(12). pii: E166. doi: 10.3390/cancers9120166. Review.


Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.

Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown LG, Nguyen HM, Pienta K, Ittmann M, Schweizer M, True LD, Wise D, Rennie PS, Vessella RL, Morrissey C, Nelson PS.

Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003.


Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.

Nyquist MD, Corella A, Burns J, Coleman I, Gao S, Tharakan R, Riggan L, Cai C, Corey E, Nelson PS, Mostaghel EA.

Mol Cancer Res. 2017 May;15(5):521-531. doi: 10.1158/1541-7786.MCR-16-0315-T.


Harnessing Solute Carrier Transporters for Precision Oncology.

Nyquist MD, Prasad B, Mostaghel EA.

Molecules. 2017 Mar 28;22(4). pii: E539. doi: 10.3390/molecules22040539. Review.


Anti-Depressant Therapy Brightens the Outlook for Prostate Cancer Bone Metastases.

Nyquist MD, Nelson PS.

Cancer Cell. 2017 Mar 13;31(3):303-305. doi: 10.1016/j.ccell.2017.02.012.


Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.

Chan SC, Selth LA, Li Y, Nyquist MD, Miao L, Bradner JE, Raj GV, Tilley WD, Dehm SM.

Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.


TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.

Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, Voytas DF, Dehm SM.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17492-7. doi: 10.1073/pnas.1308587110. Epub 2013 Oct 7.


Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression.

Nyquist MD, Dehm SM.

Horm Cancer. 2013 Apr;4(2):61-9. doi: 10.1007/s12672-013-0131-4. Epub 2013 Jan 10. Review.


Targeting G with TAL effectors: a comparison of activities of TALENs constructed with NN and NK repeat variable di-residues.

Christian ML, Demorest ZL, Starker CG, Osborn MJ, Nyquist MD, Zhang Y, Carlson DF, Bradley P, Bogdanove AJ, Voytas DF.

PLoS One. 2012;7(9):e45383. doi: 10.1371/journal.pone.0045383. Epub 2012 Sep 24.

Supplemental Content

Loading ...
Support Center